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 {#epi14683-sec-0005}

Key PointsCNV is an important contributor to the causation of epilepsy plus, with pathogenic and possibly pathogenic CNVs present in nearly 13% of casesThe use of a specifically adapted workflow to classify CNVs allows the analysis of data from retrospectively collected patients screened through different platformsThis study highlights CNVs covering recently reported (*HNRNPU*) or emerging (*RORB*) epilepsy genes, and further delineates the associated phenotypePatients with nonneurological comorbidities, especially dysmorphism, were more likely to carry pathogenic CNVs

2. INTRODUCTION {#epi14683-sec-0006}
===============

Current estimates suggest that genetics contribute to causation in 50%‐70% of the epilepsies.[1](#epi14683-bib-0001){ref-type="ref"} Copy number variations (CNVs) represent a prominent type of variant carrying risk for certain epilepsies.[2](#epi14683-bib-0002){ref-type="ref"}, [3](#epi14683-bib-0003){ref-type="ref"}, [4](#epi14683-bib-0004){ref-type="ref"}, [5](#epi14683-bib-0005){ref-type="ref"} Whole genome oligonucleotide array CGH or SNP array is routinely included in evaluation of patients with complex phenotypes with a suspected genetic cause.[6](#epi14683-bib-0006){ref-type="ref"} CNVs, as a risk factor or cause, have been reported in \~5%‐12% of patients with different types of epilepsies.[2](#epi14683-bib-0002){ref-type="ref"}, [4](#epi14683-bib-0004){ref-type="ref"}, [5](#epi14683-bib-0005){ref-type="ref"}, [7](#epi14683-bib-0007){ref-type="ref"}, [8](#epi14683-bib-0008){ref-type="ref"}, [9](#epi14683-bib-0009){ref-type="ref"} The risk of a pathogenic CNV is reportedly increased with concurrent intellectual disability (ID), dysmorphic features, autism spectrum disorder (ASD), drug resistance, or other comorbidities, from a study of 222 patients.[10](#epi14683-bib-0010){ref-type="ref"} Recurrent CNV "hotspots" predispose to different types of epilepsies.[5](#epi14683-bib-0005){ref-type="ref"}, [11](#epi14683-bib-0011){ref-type="ref"} CNV detection has pointed to novel epilepsy genes.[12](#epi14683-bib-0012){ref-type="ref"}

Robust estimates of the frequencies and types of putatively relevant CNVs in epilepsy are needed to determine whether CNV detection should be included in genetic evaluation of patients with various epilepsy phenotypes. As knowledge of epilepsy genetics increases, systematic, iterative reevaluation of genetic data becomes essential. This process requires large numbers of individuals to be corralled, and because such data will inevitably come from different centers using different technologies, a robust means of joint reevaluation is essential.

Epilepsy is often a feature of neurodevelopmental disorders (NDDs). A recent study on individuals with NDDs and epilepsy reported similar results for rare variant frequency for individuals ascertained to have epileptic encephalopathy (EE) and for individuals ascertained for NDDs with unspecified epilepsy,[13](#epi14683-bib-0013){ref-type="ref"} suggesting that, genetically, epilepsy can be considered part of the spectrum of NDDs. Looking at this concept from the perspective of CNV, and to determine the frequency of CNVs in particular epilepsy phenotypes, we assembled a large international cohort of patients with the phenotype of "epilepsy plus," which we define as the occurrence of epilepsy and comorbid features, including ID and psychiatric, neurological, and nonneurological features. Preexisting array data were systematically investigated using a workflow based on current knowledge of CNV classification. The workflow enabled combination of multicenter CNV data to provide a robust, up‐to‐date reevaluation of the contribution of CNVs to epilepsy plus and identified new candidate pathogenic autosomal CNVs. The method can be applied iteratively with additional cohorts at future time points, making optimal use of existing data.

3. MATERIALS AND METHODS {#epi14683-sec-0007}
========================

3.1. Ethics {#epi14683-sec-0008}
-----------

This study was approved by the ethics committees of the participating centers. Written informed consent was provided by the patient, or the parent or the guardian of each patient as appropriate.

3.2. Data collection {#epi14683-sec-0009}
--------------------

Preexisting CNV data, derived from array CGH or SNP array conducted for clinical or research purposes, were collected from eight specialist epilepsy and/or genetic centers (Table [S1](#epi14683-sup-0001){ref-type="supplementary-material"}). All patients also had comorbid features including ID, autism, dysmorphic features, other neurological or nonneurological conditions, structural brain abnormalities, or multidrug resistance.[14](#epi14683-bib-0014){ref-type="ref"} Clinical information was collected through referring clinicians. Seizure and epilepsy/syndrome types were classified according to the International League Against Epilepsy criteria when available.[15](#epi14683-bib-0015){ref-type="ref"}

3.3. CNV analysis: Quality control and classification {#epi14683-sec-0010}
-----------------------------------------------------

All CNV calls were provided by the contributing centers (Table [S1](#epi14683-sup-0001){ref-type="supplementary-material"}). Figure [1](#epi14683-fig-0001){ref-type="fig"} shows the workflow we used to classify CNVs (Data [S1](#epi14683-sup-0001){ref-type="supplementary-material"}). We focused only on autosomal CNVs due to higher quality of CNV calls from nonsex chromosomes.[16](#epi14683-bib-0016){ref-type="ref"} To ensure high reliability, we considered only CNVs with high calling confidence according to the following criteria: (1) size ≥ 150 kb, (2) coverage of ≥30 consecutive probes for SNP arrays and ≥3 probes for array CGH, and (3) microdeletion/microduplication frequency \< 1% in the entire study sample. Samples with a total number of deletion or duplication (or both) calls \>2 SD from the mean number of any calls/sample across the entire dataset were excluded from the analysis. Further manual analysis used a bespoke workflow based on current understanding of classification,[17](#epi14683-bib-0017){ref-type="ref"}, [18](#epi14683-bib-0018){ref-type="ref"} including the American College of Medical Genetics guidelines[19](#epi14683-bib-0019){ref-type="ref"} and additional literature.[2](#epi14683-bib-0002){ref-type="ref"}, [3](#epi14683-bib-0003){ref-type="ref"}, [4](#epi14683-bib-0004){ref-type="ref"}, [5](#epi14683-bib-0005){ref-type="ref"}, [6](#epi14683-bib-0006){ref-type="ref"}, [11](#epi14683-bib-0011){ref-type="ref"} CNVs were classified into four groups: pathogenic, possibly pathogenic, benign, or of unknown significance. Briefly, the workflow was as follows: First, common CNVs, present in the healthy population,[20](#epi14683-bib-0020){ref-type="ref"} were classified as "benign." All remaining CNVs were then classified as "pathogenic" if they met the following criteria: ≥80% overlap of the study CNV with any CNVs known to be associated with epilepsy; or, CNV with a size ≥ 3 Mb; or, CNV with a size \< 3 Mb and \> 1 Mb, and with de novo occurrence. The remaining CNVs were further classified according to their gene content. A CNV was classified as pathogenic when it involved a gene known to be associated with epilepsy ([Table S2](#epi14683-sup-0001){ref-type="supplementary-material"}), the phenotype was concordant with that in the literature, and the type of CNV (deletion/duplication) matched current knowledge on the pathogenic mechanism of the gene change (gain or loss of function). If a CNV contained a gene associated with epilepsy but the other conditions were not fulfilled, the CNV was considered pathogenic only if proven to be de novo and was otherwise classified as "possibly pathogenic." CNVs containing a brain‐expressed gene, according to the published datasets[21](#epi14683-bib-0021){ref-type="ref"} and the database GTEx (<http://www.gtexportal.org/home/>), were classified as "possibly pathogenic" only if de novo. Analysis of recessive inheritance of epilepsy genes was not considered due to limitations of most CNV platforms on calling homozygous deletions or duplications. The remaining CNVs were classified as "of unknown significance."

![Workflow used to classify the copy number variations (CNVs) in our cohort of patients with epilepsy plus. Stepwise procedures are shown for CNV classification into benign, pathogenic, possibly pathogenic, and unknown significance groups. CGH, comparative genomic hybridization; CNS, central nervous system; SNP, single nucleotide polymorphism](EPI-60-689-g001){#epi14683-fig-0001}

3.4. CNV confirmation {#epi14683-sec-0011}
---------------------

In each individual, the proposed possibly pathogenic CNVs were confirmed if DNA was available and inheritance status was confirmed using a second, locally developed technique for multiplex amplicon quantification (MAQ; Data [S1](#epi14683-sup-0001){ref-type="supplementary-material"}; Agilent, <https://www.agilent.com/en/products/next-generation-sequencing/amplicon-target-amplification-(multiplicom)/maq-overview>).

3.5. Phenotype enrichment analysis {#epi14683-sec-0012}
----------------------------------

Using Fisher\'s exact test, we investigated whether patients carrying a pathogenic autosomal CNV, compared to those not carrying a pathogenic CNV, had overrepresentation for specific phenotype components (nonneurological disorders, neurological or psychiatric disorder, ID, facial dysmorphism, brain abnormalities, epilepsy onset \< 1 year of age, and EE). The analysis was conducted in two ways---(1) for any pathogenic CNV and (2) for only large (\>1 Mb) pathogenic CNVs---and was corrected for multiple testing accordingly.

3.6. Meta‐analysis {#epi14683-sec-0013}
------------------

To determine the impact of epilepsy on the probability of identifying pathogenic CNVs, we used the following strategy. First, we split our cohort into two subgroups including patients with (1) epilepsy and ID including autistic features and (2) epilepsy and other psychiatric/neurological disorders. We gathered two "historical control groups" through a systematic review of the literature and a meta‐analysis and estimated the yield of pathogenic CNVs in patients with (1) ID including autistic features (without epilepsy) and (2) psychiatric/neurological disorders (without epilepsy). Then, we compared the yield of pathogenic CNVs between these groups with (1) epilepsy and ID including autistic features versus the historical‐control group with only ID and autistic features and (2) epilepsy with other psychiatric/neurological disorders versus the corresponding control group from the literature manifesting only other psychiatric/neurological disorders. We used the Cochran Q test to assess heterogeneity across studies.

To evaluate whether epileptic encephalopathies might specifically contribute to the yield of pathogenic CNVs, we compared patients with epilepsy manifesting as EE (epilepsy‐EE) from our cohort to those with epilepsy without EE (epilepsy‐notEE) from a systematic review of the literature.

The full search strategy, inclusion criteria, and methods are available in Data [S1](#epi14683-sup-0001){ref-type="supplementary-material"}.

4. RESULTS {#epi14683-sec-0014}
==========

We assembled a cohort of 1255 patients. After quality control, 1097 patients were retained for analysis. Of these, 139 (12.7%) carried a total of 142 autosomal CNVs classified as either pathogenic (n = 122, 10.9%) or possibly pathogenic (n = 20, 1.7%). Eleven patients (1%) carried two pathogenic or possibly pathogenic CNVs ([Table S3](#epi14683-sup-0001){ref-type="supplementary-material"}).

4.1. Pathogenic CNVs {#epi14683-sec-0015}
--------------------

To simplify presentation, we further divided pathogenic CNVs into four subgroups: (1) recurrent CNVs with well‐documented enrichment in epilepsy; (2) CNVs related to a genetic Online Mendelian Inheritance in Man database (OMIM) syndrome with neurological symptoms in which epilepsy can feature; (3) CNVs not known to be enriched in epilepsy and not associated with any other OMIM syndrome, but containing at least one gene that is already implicated in epilepsy; and (4) CNVs based on size combined with de novo occurrence.

### 4.1.1. Recurrent CNVs with well‐documented enrichment in epilepsy {#epi14683-sec-0016}

Thirty‐six individuals had a CNV known to be recurrent in people with epilepsy (36/120, 30%; Table [1](#epi14683-tbl-0001){ref-type="table"}).[2](#epi14683-bib-0002){ref-type="ref"}, [5](#epi14683-bib-0005){ref-type="ref"}, [11](#epi14683-bib-0011){ref-type="ref"} One individual had two recurrent pathogenic CNVs. The 16p13.11 deletion was the most frequent, occurring in 10 of 120 (8.3%) patients bearing pathogenic CNVs and 10 of 1097 (0.9%) of the studied individuals. Other frequently represented CNVs were 1p36 deletion (OMIM \#607872, 5/120 patients, 4.2%), 15q11.2 deletion (OMIM \#615656, 5/120 patients, 4.2%), and 22q11.2[19](#epi14683-bib-0019){ref-type="ref"} duplication (OMIM \#608363, 5/120 patients, 4.2%).

###### 

Recurrent CNVs with well‐documented enrichment in epilepsy

  Samples, n   Chr region   CNV type      Syndrome                                       OMIM/reference boundaries   OMIM or references
  ------------ ------------ ------------- ---------------------------------------------- --------------------------- ---------------------------------------------------------------------------------------
  5            1p36         Deletion      Chromosome 1p36 deletion syndrome              1:1‐27 600 000              \#607872
  2            1q21.1       Deletion      Chromosome 1q21.1 deletion syndrome            1:143 200 000‐147 500 000   \#612474
  1            1q21.1       Duplication   Chromosome 1q21.1 duplication syndrome         1:143 200 000‐147 500 000   \#612475
  5            15q11.2      Deletion      Chromosome 15q11.2 deletion syndrome           15:20 500 000‐25 500 000    \#615656
  3            15q13.3      Deletion      Chromosome 15q13.3 deletion syndrome           15:30 900 000‐33 400 000    \#612001
  3            16p11.2      Deletion      Chromosome 16p11.2 deletion syndrome           16:28 500 000‐35 300 000    \#611913
  10           16p13.11     Deletion      Chromosome 16p13.11 deletion syndrome          16:15 000 000‐16 300 000    Refs [3](#epi14683-bib-0003){ref-type="ref"}, [4](#epi14683-bib-0004){ref-type="ref"}
  3            22q11.21     Deletion      Chromosome 22q11.2 deletion syndrome, distal   22:17 400 000‐25 500 000    \#611867
  5            22q11.21     Duplication   Chromosome 22q11.2 duplication syndrome        22:17 400 000‐25 500 000    \#608363

CNV, copy number variation; OMIM, Online Mendelian Inheritance in Man database.
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### 4.1.2. CNVs related to a genetic OMIM syndrome with neurological symptoms in which epilepsy can feature {#epi14683-sec-0017}

Thirty‐three individuals had pathogenic CNVs (33/120, 27.5%) mapping to regions for well‐characterized genetic syndromes associated with neurological features including epilepsy ([Table S4a](#epi14683-sup-0001){ref-type="supplementary-material"}) and consistent with the relevant syndrome. The most frequent were as follows: the Williams‐Beuren 7q11.23 deletion syndrome (five patients), 15q11.2 duplication syndrome, distal (three patients), 16p11.2 duplication syndrome including *PRRT2* (four patients), the Potocki‐Lupski 17p11.2 duplication syndrome (two patients), and 17p13.3 deletion syndrome, also known as Miller‐Dieker lissencephaly deletion syndrome (three patients). We also identified de novo duplications at 2q24.3[22](#epi14683-bib-0022){ref-type="ref"} and at 4p16.3‐p13,[23](#epi14683-bib-0023){ref-type="ref"} for which regions both deletions and reciprocal duplications have been associated with epilepsy.[22](#epi14683-bib-0022){ref-type="ref"}, [23](#epi14683-bib-0023){ref-type="ref"}

### 4.1.3. CNVs including epilepsy‐related genes {#epi14683-sec-0018}

Nineteen individuals had a CNV (19/120, 15.8%) including epilepsy‐related genes (Table [2](#epi14683-tbl-0002){ref-type="table"}). Five individuals had a CNV including *HNRNPU* (four de novo deletions and one duplication; two deletions and the duplication also contained the flanking *AKT3* gene). The four probands carrying deletions presented with epilepsy classified as Lennox‐Gastaut syndrome in one patient, genetic generalized epilepsy (GGE) in another, and early onset, drug‐resistant epilepsy not otherwise classified in the remaining two. Moderate to severe ID was reported in four patients and one also had ASD. Three had microcephaly, congenital and severe (−4 SD) in one. Brain magnetic resonance imaging showed corpus callosum agenesis or hypoplasia in three of four patients. Facial dysmorphic features were observed in three patients. The patient carrying a large (\>100 Mb) duplication involving, among many other genes, *HNRNPU* and *AKT3*, had a complex phenotype including neonatal seizure onset, polymicrogyria, and multiple cardiac defects. Three individuals had a 9q21.13 deletion, one de novo and two of unknown inheritance, including a gene with recently described association with epilepsy, *RORB*. All the patients presented with ID and generalized epilepsy with absences or atypical absences, with eyelid myoclonia in two cases and photosensitivity in one. Further clinical details of patients with CNVs including *HNRNPU* or *RORB* are provided in [Tables S5a and S5b](#epi14683-sup-0001){ref-type="supplementary-material"}. Three deletions encompassed the *ADGRV1* gene, two of which included *MEF2C*. Additional epilepsy genes that were found deleted or duplicated in single patients are listed in Table [2](#epi14683-tbl-0002){ref-type="table"} and include *GNAO1*,*NEDD4L*, and *SIK1*.

###### 

CNVs including epilepsy‐related genes

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Individual   CNV type      Chr region        Start       Stop        Size, Mb   Inheritance   Epilepsy genes     Epilepsy phenotype                                       Other clinical features                                                                                                                                                                                                                         Neuroimaging                                                                                                                                                                                      Reported epilepsy phenotype associated with genes                                                                                                                                                                              Proposed disease mechanism (gain or loss of function) of reported epilepsy genes
  ------------ ------------- ----------------- ----------- ----------- ---------- ------------- ------------------ -------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -----------------------------------------------------------------------------------------------------------------
  IT_FLO_041   Deletion      1q42‐q44          236852056   249212809   12.4       De novo       *HNRNPU, AKT3*     Epilepsy NOS, DR                                         ID, stereotypies, congenital microcephaly (−4 SD), facial dysmorphism                                                                                                                                                                           CC agenesis, holoprosencephaly                                                                                                                                                                    *HNRNPU*: epileptic encephalopathy, early infantile, 54 (MIM 617391)\                                                                                                                                                          Loss of function ([Table S6a](#epi14683-sup-0001){ref-type="supplementary-material"});\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              *AKT*3: megalencephaly, polymicrogyria, polydactyly, hydrocephalus syndrome 2 (MIM 615937)                                                                                                                                     loss and Gain of function ([Table S6a](#epi14683-sup-0001){ref-type="supplementary-material"} for more details)

  BE_LEU_127   Duplication   1q21.1‐q44        144967252   249212666   104.2      Unknown       *HNRNPU, AKT3*     Epilepsy NOS with infantile onset, DR                    Hypotonia, respiratory insufficiency, cardiac defects (large aorta ascendens and aortic arch, open ductus Botalli, ASD2 with small left/right shunt; pulmonary hypoplasia), kidney malrotation, facial dysmorphism                              Widening of lateral ventricles and cavum vergae, polymicrogyria                                                                                                                                                                                                                                                                                                                                                                  

  PO_W\_031    Deletion      1q43‐q44          241757184   245072885   3.3        De novo       *HNRNPU, AKT3*     Focal of unknown origin                                  ID, hypotonia, acquired microcephaly (−2 SD), facial dysmorphism, hypotonia                                                                                                                                                                     Frontal lobe atrophy and CC hypoplasia                                                                                                                                                                                                                                                                                                                                                                                           

  IT_FLO_062   Deletion      1q44              244515959   247118959   2.6        De novo       *HNRNPU*           Generalized epilepsy, DR                                 ID, facial dysmorphism, GH deficit, deafness, acquired microcephaly (−2 SD), joint hyperlaxity, scoliosis                                                                                                                                       CC hypoplasia, ventricle asymmetry                                                                                                                                                                                                                                                                                                                                                                                               

  BE_LEU_009   Deletion      1q44              244823848   248093878   3.3        De novo       *HNRNPU*           Lennox‐Gastaut syndrome                                  ID, scoliosis, gastroesophageal reflux, bilateral corneal opacity                                                                                                                                                                               Delayed myelination, atrophic septum pellucidum, aqueduct stenosis, hydrocephaly                                                                                                                                                                                                                                                                                                                                                 

  BE_ANT_005   Deletion      2q24.3            163860225   172528095   8.7        De novo       *SCN1A, SCN2A*     Generalized epilepsy of unknown origin                   ID, facial dysmorphism                                                                                                                                                                                                                          Negative                                                                                                                                                                                          *SCN1A*: epileptic encephalopathy, early infantile, 6 (Dravet syndrome; MIM 607208); epilepsy, generalized, with febrile seizures plus, type 2 (MIM 604403); febrile seizures, familial, 3A (MIM 604403);\                     Loss of function; loss of function is associated with ASD, gain of function is associated with EE
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              *SCN2A*: epileptic encephalopathy, early infantile, 11 (MIM 61372); seizures, benign familial infantile, 3 (MIM 6077451)                                                                                                       

  IT_FLO_020   Deletion      5q14.3            88232244    90181244    1.9        De novo       *ADGRV1*           Epilepsy and FS NOS                                      None                                                                                                                                                                                                                                            Abnormal NOS                                                                                                                                                                                      *ADGRV1*: febrile seizures, familial, 4 (MIM 604352); myoclonic epilepsy ([Table S2](#epi14683-sup-0001){ref-type="supplementary-material"});\                                                                                 Loss of function
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              *MEF2C*: mental retardation, stereotypic movements, epilepsy, and/or cerebral malformations (MIM 613443)                                                                                                                       

  PO_W\_027    Deletion      5q14.3‐q15        87100153    92514871    5.4        De novo       *ADGRV1, MEF2C*    Epilepsy NOS                                             ID, dysmorphism                                                                                                                                                                                                                                 NA                                                                                                                                                                                                                                                                                                                                                                                                                               

  IT_FLO_024   Deletion      5q14q21           87770000    95780000    8          Unknown       *ADGRV1, MEF2C*    Epilepsy NOS                                             ID, macrocephaly, facial dysmorphism                                                                                                                                                                                                            Periventricular nodular heterotopia                                                                                                                                                                                                                                                                                                                                                                                              

  BE_LEU_211   Deletion      5q34              161059999   161446505   0.4        Unknown       *GABRA1, GABRA6*   Epilepsy NOS                                             ID                                                                                                                                                                                                                                              Corticosubcortical atrophy, supratentorial ventricular enlargement, periventricular vascular leukoencephalopathy, white matter lesions, lacunar infarcts in the basal ganglia and left thalamus   *GABRA1*: epileptic encephalopathy, early infantile, 19 (MIM 615744); possible susceptibility allele; juvenile myoclonic epilepsy (MIM 611136) and childhood absence epilepsy (MIM 611136);\                                   Loss of function
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              *GABRA6*: possible susceptibility allele for childhood absence epilepsy ([Table S2](#epi14683-sup-0001){ref-type="supplementary-material"})                                                                                    

  PO_W\_019    Deletion      9q21.13           74741400    77306932    2.6        De novo       *RORB*             Generalized photosensitive epilepsy (Jeavons syndrome)   ID, autism, strabismus                                                                                                                                                                                                                          Negative                                                                                                                                                                                          Generalized epilepsy, ID ([Table S6b](#epi14683-sup-0001){ref-type="supplementary-material"} for more details)                                                                                                                 Loss of function

  BE_LEU_244   Deletion      9q21.13           76474486    81651005    5.2        Unknown       *RORB*             Generalized of unknown origin                            ID, episodic ataxia                                                                                                                                                                                                                             Small nonspecific white matter lesions over right parietal hemisphere                                                                                                                                                                                                                                                                                                                                                            

  US_267       Deletion      9q21.12‐q21.13    72702925    77128468    4.4        Unknown       *RORB*             Generalized epilepsy of unknown origin                   ID, pyramidal sign, tremor, neurogenic bladder, psychotic episodes, severe macrocytic anemia, cold agglutinin disease, bilateral femuropatellar arthrosis, facial dysmorphisms                                                                  NA                                                                                                                                                                                                                                                                                                                                                                                                                               

  BE_LEU_205   Deletion      12p13.31          8691730     14215925    5.5        Unknown       *GRIN2B*           Focal epilepsy of unknown origin                         ID, facial dysmorphism                                                                                                                                                                                                                          Negative                                                                                                                                                                                          Epileptic encephalopathy, early infantile, 27 (MIM 616139)                                                                                                                                                                     Loss and gain of function

  PO_W\_017    Duplication   14q11.2‐q12       23309096    31675172    8.3        De novo       *FOXG1*            Epilepsy NOS                                             ID                                                                                                                                                                                                                                              NA                                                                                                                                                                                                Rett syndrome, congenital variant (MIM 613454)                                                                                                                                                                                 Loss of function

  IT_FLO_033   Deletion      16q12.1‐q21       52347499    64578499    12.2       Unknown       *GNAO1, GPR56*     Generalized epilepsy of structural origin                ID, language delay, facial dysmorphism, microcephaly, cryptorchidism                                                                                                                                                                            Polymicrogyria                                                                                                                                                                                    *GNAO1*: epileptic encephalopathy, early infantile, 17 (MIM 615473); neurodevelopmental disorder with involuntary movements (MIM 617493); movement disorder with or without EE; *GPR56*: polymicrogyria (MIM 606854, 615752)   Loss of function;\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             gain of function (recessive, loss of function)

  IT_FLO_017   Deletion      18q21.31‐q21.33   54687002    59222020    4.5        Unknown       *NEDD4L*           Focal epilepsy of unknown origin                         ID, hypotonia, dyspraxia, clumsiness, convergent strabismus                                                                                                                                                                                     Vermis hypoplasia                                                                                                                                                                                 OMIM: periventricular nodular heterotopia (MIM 617201; Lennox‐Gastaut syndrome--infantile spasms)                                                                                                                              Loss of function

  IT_FLO_074   Deletion      20q13.33          61845191    62893189    1.1        De novo       *KCNQ2, CHRNA4*    Generalized epilepsy of structural origin                Bilateral deafness, facial dysmorphism, lumbar kyphosis, sacral dimple, bilateral clinodactyly, small hands and fingers, hypoplastic flexion creases, atrial and ventricular septal defects, left renal agenesis defects, left renal agenesis   Periventricular nodular heterotopia                                                                                                                                                               *KCNQ2*: epileptic encephalopathy, early infantile, 7 (MIM 613720); myokymia (MIM 121200); seizures, benign neonatal, 1 (MIM 121200);\                                                                                         Gain and loss of function;\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              *CHRNA4*: epilepsy, nocturnal frontal lobe, 1 (MIM 600513)                                                                                                                                                                     loss and gain of function

  US_073       Deletion      21q22.3           43420839    46944323    3.5        Unknown       *SIK1*             Generalized epilepsy of unknown origin                   ID, ataxia, spasticity, kyphoscoliosis, aortic valve deficiency                                                                                                                                                                                 Enlarged lateral ventricles with pronunciation of occipital horns (colpocephaly)                                                                                                                  Epileptic encephalopathy, early infantile, 30 (MIM 616341)                                                                                                                                                                     Loss of function
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The reported phenotype associated with each known epilepsy gene refers to the phenotype reported in the OMIM or, if not available, the citation indicated in the supplementary material ([Table S2](#epi14683-sup-0001){ref-type="supplementary-material"}).

ASD, atrial septal defects; CC, corpus callosum; CNV, copy number variation; DR, drug‐resistant; EE, epileptic encephalopathy; FS, febrile seizures; GH, growth hormone; ID, intellectual disability; MIM, Mendelian Inheritance in Man; NA, not available; NOS, not otherwise specified; OMIM, Online Mendelian Inheritance in Man database.
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### 4.1.4. Pathogenic autosomal CNVs based on size combined with de novo occurrence {#epi14683-sec-0019}

Thirty‐two individuals (32/120, 26.6%) had CNVs that fell only into this category (one individual had two large pathogenic CNVs). We did not find overlapping CNVs in healthy individuals (Database of Genomic Variants; <http://dgv.tcag.ca/dgv/app/home>). Sixteen (16/32, 50%) of the CNVs ≥ 3 Mb showed an overlap or partial overlap with CNVs described in Decipher (<https://decipher.sanger.ac.uk/>) in patients exhibiting various clinical features including ID, seizures, and dysmorphisms ([Table S4b](#epi14683-sup-0001){ref-type="supplementary-material"}). Interestingly, in a patient with an EE, we uncovered a de novo 13q33.1‐q13.3 deletion including *NBEA*.

### 4.1.5. Possibly pathogenic CNVs {#epi14683-sec-0020}

Nineteen individuals (19/1097, 1.73%) had a total of 20 CNVs classified as possibly pathogenic (one individual had two possibly pathogenic CNVs); 10 were de novo (Table [3](#epi14683-tbl-0003){ref-type="table"}). For 17 of 19 individuals (18/20 CNVs), DNA was available to check the CNV and/or inheritance using MAQ analysis. Eleven of the 18 analyzed CNVs were confirmed; in seven cases, the test was inconclusive (Table [3](#epi14683-tbl-0003){ref-type="table"}). These CNVs were classified as possibly pathogenic because they included an epilepsy gene but were inherited or the direction of the change was not concordant with the known disease mechanism (loss or gain of function) or phenotype, or because they included a brain‐expressed gene and were de novo. CNVs falling in the first category were a maternally inherited 10q23 deletion including *LGI1*, and a maternally inherited 20q13 duplication including *KCNQ2*,*CHRNA4*, and *EEF1A2*. Four other inherited CNVs included recessive genes: *PLCB1*,*TBC1D24*,*ABAT*, and *CNTNAP2*. A possible additional single nucleotide variant (SNV) on the other allele cannot be excluded. Of note, the *PLCB1* deletion was confirmed to be homozygous and would be considered pathogenic, but our flowchart was not developed for recessive analysis.

###### 

Autosomal CNVs classified as "possibly pathogenic"

  Individual                                          CNV type      Chr region       Start       Stop        Size, Mb   Inheritance                                              Proposed candidate genes[a](#epi14683-note-0010){ref-type="fn"}   Epilepsy phenotype                           Other clinical features                                                                                    Neuroimaging                                                                       MAQ validation
  --------------------------------------------------- ------------- ---------------- ----------- ----------- ---------- -------------------------------------------------------- ----------------------------------------------------------------- -------------------------------------------- ---------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- ----------------------------------------
  BE_LEU_009                                          Duplication   1q43             239842929   240356854   0.5        De novo                                                  *FMN2* (start BP within gene), *CHRM3* (stop BP within gene)      Epilepsy NOS                                 ID, scoliosis, gastroesophageal reflux, bilateral corneal opacity                                          Delayed myelination, atrophic septum pellucidum, aqueduct stenosis, hydrocephaly   De novo
  US_184                                              Duplication   3q28             191886383   192432844   0.5        De novo                                                  *FGF12* (intragenic duplication)                                  Epilepsy NOS                                 Learning disabilities, attention deficit                                                                   Malrotation anterior and central part left hippocampus                             NA
  BE_LEU_141                                          Deletion      3q22.3           136035522   136412948   0.4        De novo                                                  *STAG1, PCCB* (start BP within gene)                              Epilepsy NOS                                 ID, autism, hypertonia, scoliosis,                                                                         NA                                                                                 Confirmed in patient, absent in mother
  IT_FLO_036[b](#epi14683-note-0010){ref-type="fn"}   Duplication   4q21.22‐q21.23   84035965    84813544    0.8        De novo                                                  *COQ2* (stop BP within gene)                                      Myoclonic‐atonic epilepsy                    ID                                                                                                         Negative                                                                           De novo
  IT_FLO_127                                          Deletion      5q23.2           122481284   122987185   0.5        De novo                                                  *CEP120, CSNK1G3* (stop BP within gene)                           Myoclonic epilepsy                           ID, hypotonia                                                                                              Negative                                                                           De novo
  PO_W\_039                                           Duplication   7q35‐q36.1       146934489   148471787   1.5        Inherited (M)                                            *CNTNAP2* (start BPs within gene)                                 Epilepsy NOS                                 ID                                                                                                         CC hypoplasia                                                                      Inconclusive
  IT_FL0_131                                          Deletion      6q26             161725639   161878527   0.2        De novo                                                  *PARK2* (stop BP within gene)                                     Epilepsy NOS, FS                             ID, hypotonia, obesity crowding of the fingers in both hands and feet, onychodystrophy                     NA                                                                                 Inconclusive
  Deletion                                            12p12.3       15469971         16375910    0.9         De novo    *STRAP*                                                                                                                                                                                                                                                                                                                                                               
  IT_FLO_109                                          Duplication   8p23.3‐p23.2     161272      801514      0.6        Unbalanced segregation of a balanced translocation (M)   *FBXO25*                                                          Generalized epilepsy of unknown origin, DR   Language disorder                                                                                          Negative                                                                           Inconclusive
  IT_FLO_134                                          Deletion      8p23.3‐23.2      221611      801373      0.6        Unbalanced segregation of a balanced translocation (M)   *FBXO25*                                                          Myoclonic epilepsy, FS                       No                                                                                                         NA                                                                                 Inconclusive
  BE_LEU_236                                          Duplication   9q22.31          95208377    95590171    0.4        De novo                                                  *BICD2*                                                           Epilepsy NOS                                 ID                                                                                                         NA                                                                                 De novo
  IT_FLO_144                                          Deletion      10q23.33         95490322    95791986    0.3        Inherited (M)                                            *LGI1*                                                            Epileptic encephalopathy NOS                 Severe ID, quadriplegia, congenital cardiomyopathy (implanted pacemaker)                                   Cerebral atrophy microcephaly                                                      Maternally inherited
  BE_LEU_012                                          Duplication   15q13.2                      32509932    1.6        Inherited (P)                                            *CHRNA7*                                                          Focal of unknown origin                      ID                                                                                                         No                                                                                 Inconclusive
  UK_L\_056                                           Duplication   16p13.3          2481289     2888632     0.4        Unknown                                                  *TBC1D24*                                                         Myoclonic‐atonic epilepsy                    ID                                                                                                         Negative                                                                           Confirmed in proband, parents NA
  US_175                                              Deletion      16p13.2          8368145     8860296     0.5        Inherited (M)                                            *ABAT* (stop BP within gene)                                      Epileptic encephalopathy NOS                 ID, apraxia, dyskinesia, generalized hypotonia                                                             Negative                                                                           Maternally inherited
  IT_FLO_023                                          Deletion      17q21.31         43160474    43922220    0.8        De novo                                                  *NMT1* (start BP within gene), *PLCD3* (start BP within gene)     Focal epilepsy of unknown origin, FS         ID, macrocephaly, facial dysmorphism, cardiac defect, skin dyschromia                                      CC hypoplasia                                                                      Inconclusive
  IT_FLO_083                                          Deletion      18q12.3          42605437    42784321    0.2        De novo                                                  *SETBP1* (start BP within gene)                                   Generalized epilepsy of unknown origin, DR   ID                                                                                                         Negative                                                                           De novo
  BE_LEU_116                                          Duplication   19p13.3          538568      2268870     1.7        Unknown                                                  *HCN2*                                                            Epilepsy NOS and FS                          Learning disabilities, ADHD, facial dysmorphism                                                            Negative                                                                           Confirmed in proband, parents NA
  US_124                                              Deletion      20p12.3          8314301     8688028     0.4        Inherited (M+P)                                          *PLCB1* (start BP within gene)                                    Epileptic encephalopathy NOS                 Profound ID, microcephaly, hypertonia, hyperreflexia more prominent on the left side, squint in left eye   Atrophy on CT brain                                                                NA
  PO_W\_030                                           Duplication   20q13.33         61925286    62724437    0.8        Inherited (M)                                            *KCNQ2, CHRNA4, EEF1A2*                                           Focal epilepsy of unknown origin             ID, facial dysmorphism                                                                                     NA                                                                                 Confirmed in proband, parents NA

ADHD = attention‐deficit/hyperactivity disorder; BP = breakpoint; CC = corpus callosum; CNV = copy number variation; CT = computed tomography; DR = drug resistant; FS = febrile seizures; ID = intellectual disability; M = maternal; MAQ = multiplex amplicon quantification; NA = not available; NOS = not otherwise specified; P = paternal.

Column with candidate genes also includes CNVs including known epilepsy genes that have not been considered pathogenic for various reasons; for example, the direction of the change or the phenotype did not fit to what is reported in the literature, or the CNV was inherited from a parent with unknown affectedness status.

Reported in Ottaviani et al.[43](#epi14683-bib-0043){ref-type="ref"}

John Wiley & Sons, Ltd

In the second category, we identified several interesting candidate genes including a de novo deletion including *STAG1* and a de novo intragenic duplication in *FGF12*. In both genes, only recently have pathogenic SNVs been reported in patients with neurodevelopmental disorders including epilepsy.[24](#epi14683-bib-0024){ref-type="ref"}, [25](#epi14683-bib-0025){ref-type="ref"} We further identified a deletion including *SETBP1* associated with Shinzel‐Gieidon syndrome and ID (OMIM 611060) and a duplication including *HCN2,* a gene in which SNVs exerting a gain‐of‐function effect have recently been suggested as a risk factor for genetic generalized epilepsies.[26](#epi14683-bib-0026){ref-type="ref"} *HCN2* has also previously been associated with febrile epilepsy syndromes; interestingly, the patient carrying this CNV also had a history of febrile seizures.[27](#epi14683-bib-0027){ref-type="ref"} Other interesting candidate genes located in identified de novo deletions or possibly disrupted by intragenic breakpoints of identified duplications included *FMN2* (also associated with AR mental retardation MIM616193), *CHRM3*,*CSNK1G3*, and *NMT1*, all of which are brain‐expressed and predicted to be intolerant to loss of function (probability of loss‐of‐function intolerance ≥ 0.99) according to the latest gnomAD (<http://gnomad.broadinstitute.org/about>) constraint metrics (<https://www.nature.com/articles/nature19057>).

4.2. Enrichment analysis {#epi14683-sec-0021}
------------------------

We collected phenotypic information on seven characteristics wherever this specific information was available: neurological or psychiatric disorder (528/956 patients, 55.2%), ID (727/944 patients, 77%), comorbidity with a nonneurological disorder (242/882 patients, 27.4%), facial dysmorphism (209/769 patients, 27.2%), brain abnormalities (288/613 patients, 47%), epilepsy onset before 1 year of age (175/340 patients, 51.5%), and diagnosis of known EE syndrome (238/487 patients, 49%). We compared carriers of pathogenic autosomal CNVs with those who did not carry a pathogenic autosomal CNV. Patients with pathogenic CNVs were significantly enriched for nonneurological disorders (2.68‐fold) and for dysmorphism (4.09‐fold; Figure [2](#epi14683-fig-0002){ref-type="fig"}). Beyond the overall pathogenic CNV enrichment, testing for large pathogenic CNVs (\>1 Mb) separately showed a more profound and significant fold enrichment of 2.82 and 4.94 for comorbidity with nonneurological disorder and dysmorphism, respectively (Figure [2](#epi14683-fig-0002){ref-type="fig"}).

![Enrichment analysis. Left panel: Across all patients analyzed in this study, those affected with a pathogenic copy number variation (CNV) were significantly enriched for being comorbid with a nonneurological disorder or dysmorphism. Right panel: Restriction of the analysis to patients carrying large pathogenic CNVs (\>1 Mb). These CNV carriers are particularly enriched for nonneurological disorders and dysmorphism. Odds ratios (ORs) significant beyond correction for multiple testing are denoted by triangles](EPI-60-689-g002){#epi14683-fig-0002}

4.3. Meta‐analysis {#epi14683-sec-0022}
------------------

The search identified 4806 citations, of which 59 papers met the inclusion criteria and were included in the systematic review. Overall meta‐analysis showed that in patients with ID without epilepsy, the yield of pathogenic CNVs was 15% (95% confidence interval \[CI\] = 14‐17), and in patients with psychiatric/neurological disorders without epilepsy, the yield was 8% (95% CI = 5‐12; [Figure S3](#epi14683-sup-0001){ref-type="supplementary-material"}, Table [4](#epi14683-tbl-0004){ref-type="table"}). These data were compared with the two subgroups from our cohort: (1) patients with epilepsy and intellectual disabilities, including autistic features, with a yield of 13.5% (95% CI = 9.2‐18.9); and (2) patients with epilepsy and psychiatric/neurological comorbidities, with a yield of 10% (95% CI = 7.9‐11.7). We did not find statistically significant differences for any of these comparisons (*P* values from heterogeneity test were \>0.05).

###### 

Comparison of the yield of pathogenic copy number variations in three subgroups of patients from this study with respect to three groups of patients from the literature, analyzed through meta‐analysis

  Yield from this study   Yield from meta‐analysis                                  *P* from test of heterogeneity                                                      
  ----------------------- --------------------------------------------------------- -------------------------------- ------------------------------------ ------------- --------
  a                       ID + epilepsy (207)                                       28/207 = 13.5% (9.2‐18.9)        ID                                   15% (14‐17)   0.4491
  b                       Psychiatric/neurological comorbidities + epilepsy (528)   53/528 = 10.0% (7.9‐11.7)        Psychiatric/neurological disorders   8% (5‐12)     0.3962
  c                       Epilepsy‐EE (238)                                         17/238 = 7.1% (4.2‐11.2)         Epilepsy‐notEE                       11% (8‐14)    0.1251

CI, confidence interval; EE, epileptic encephalopathy; ID, intellectual disability.

John Wiley & Sons, Ltd

The yield of pathogenic CNVs in patients with epilepsy‐EE from our cohort (7.1%, 95% CI = 4.2‐11.2) was lower, but not significantly different, than in patients with epilepsy‐notEE from the meta‐analysis (11%, 95% CI = 8‐14; Table [4](#epi14683-tbl-0004){ref-type="table"}).

5. DISCUSSION {#epi14683-sec-0023}
=============

Most epilepsies, especially when beginning in infancy and childhood, have a prominent genetic contribution. Numerous next generation sequencing, whole exome sequencing, and whole genome sequencing studies have been published in recent years uncovering single gene mutations in many epilepsies and epilepsy syndromes. Yet, the contribution of CNVs to the epilepsies, especially those complicated by comorbidities, has been less explored. Most published reports are single‐center studies. The largest sample size was 2454 patients including a large cohort of 1366 patients with genetic generalized epilepsy in addition to 281 patients with rolandic epilepsy and 807 patients with adult focal epilepsy[28](#epi14683-bib-0028){ref-type="ref"}, [29](#epi14683-bib-0029){ref-type="ref"}; the biggest cohort specifically addressing the epilepsy plus phenotype studied 222 individuals.[4](#epi14683-bib-0004){ref-type="ref"} The maximum frequency of pathogenic CNVs reported in any of these series was 12%, with a range of 5%‐12%. These studies tended to focus on individuals who were children at the time of testing.[2](#epi14683-bib-0002){ref-type="ref"}, [5](#epi14683-bib-0005){ref-type="ref"}, [9](#epi14683-bib-0009){ref-type="ref"} The importance of rare CNVs has been well recognized in patients with neuropsychiatric disorders including unexplained ID, congenital anomalies, and seizures. Thus, clinical geneticists, pediatric neurologists, and epileptologists commonly request chromosomal array CGH to obtain a genetic diagnosis for patients with such clinical features.

However, CNVs may be seen in healthy control individuals, and determination of the pathogenicity of newly identified CNVs can be challenging. To evaluate the role of pathogenic CNVs and identify possible candidate genes, we investigated the occurrence of CNVs in epilepsy plus, in a cohort among the largest reported to date.[2](#epi14683-bib-0002){ref-type="ref"}, [3](#epi14683-bib-0003){ref-type="ref"}, [4](#epi14683-bib-0004){ref-type="ref"}, [5](#epi14683-bib-0005){ref-type="ref"}, [9](#epi14683-bib-0009){ref-type="ref"} Data were collected from eight centers and included both adults and children. Autosomal CNV classification was conducted using a systematic filtering procedure specifically adapted to epilepsy. The workflow was an essential tool to identify, reanalyze, and reinterpret CNVs in this retrospectively collected cohort, in which CNV testing had been performed using different platforms in different laboratories. About 11% of patients with epilepsy plus harbored a pathogenic autosomal CNV. This number reaches 12.7% when we also consider the possibly pathogenic CNVs. Previous similar studies report a diagnostic yield ranging from \~5% to 12%.[2](#epi14683-bib-0002){ref-type="ref"}, [3](#epi14683-bib-0003){ref-type="ref"}, [4](#epi14683-bib-0004){ref-type="ref"}, [5](#epi14683-bib-0005){ref-type="ref"}, [8](#epi14683-bib-0008){ref-type="ref"}, [9](#epi14683-bib-0009){ref-type="ref"} Thus, our result fits at the upper limit of this range, probably mainly due to the "epilepsy plus" phenotype of our cohort and to the application of a standardized workflow. Previously published studies[3](#epi14683-bib-0003){ref-type="ref"}, [4](#epi14683-bib-0004){ref-type="ref"}, [8](#epi14683-bib-0008){ref-type="ref"} that reported similar yields of pathogenic CNVs (9.3%, 8.1%, and 12%, respectively) also examined patients with complex epilepsy including ID. Overall, results from both our and similar previous studies indicate that within the complex phenotype of neurodevelopmental disorders, when seizures are associated with ID or with other neurological and nonneurological comorbidities, there is a higher probability of identifying a pathogenic CNV than in epilepsy alone.

We checked the original classification, where available (138/142), of pathogenic and possibly pathogenic CNVs before and after applying the workflow method we propose here. We found that 7.2% (10/138) of cases were discrepant. The main direction of change was from CNVs (8/10 CNVs) originally classified as of "unknown significance" to "pathogenic" and "possibly pathogenic" ([Table S7](#epi14683-sup-0001){ref-type="supplementary-material"}). This is expected as information about brain‐expressed genes or gene regions associated with epilepsy increases. We have confirmed that reanalysis of existing data over time is essential.

Our study confirms the importance of specific CNVs in epilepsy and broadens some of the associated phenotypic spectra.

Recurrent microdeletions at 1q21.1, 15q11.2, 15q13.3, 16p13.11, and 22q11.21 have been reported as risk factors for GGEs and focal epilepsies.[28](#epi14683-bib-0028){ref-type="ref"}, [29](#epi14683-bib-0029){ref-type="ref"} The most frequent CNV identified in our cohort was the 16p13.11 deletion, which accounts for 8.3% of the pathogenic CNVs, supporting a marked relevance in the clinical setting.

We also found several CNVs that included the genes *HNRNPU* (1q44) and *RORB* (9p21.13), both recently associated with epilepsy.[28](#epi14683-bib-0028){ref-type="ref"}, [30](#epi14683-bib-0030){ref-type="ref"}, [31](#epi14683-bib-0031){ref-type="ref"}, [32](#epi14683-bib-0032){ref-type="ref"} Microdeletions of the 1q43q44 critical region have been associated with ID, dysmorphism, abnormalities of the corpus callosum, and seizures.[30](#epi14683-bib-0030){ref-type="ref"} This critical region includes *HNRNPU* as the most relevant candidate epilepsy gene. Around 30 point mutations, mainly including truncating, splice‐site, and a few missense variants, in *HNRNPU* have recently been identified in individuals with ID and seizures ([Table S6a](#epi14683-sup-0001){ref-type="supplementary-material"}). In our cohort, five patients carried CNVs mapping to the 1q43q44 critical region, and in addition to the *HNRNPU* gene, in two duplications and one deletion, the chromosomal rearrangement included also the *AKT3* gene, which might contribute to brain abnormalities observed in these patients. Patients with deletions showed dysmorphic features, early onset psychomotor delay, and early onset epilepsy. These data confirm the role of *HNRNPU* in neurodevelopment and epileptogenesis.

Mutations in *RORB* were first reported in a patient with mild ID and partial epilepsy.[31](#epi14683-bib-0031){ref-type="ref"} More recently, other mutations were identified in patients with neurodevelopmental disorders and mostly GGE, including absence seizures ([Table S6b](#epi14683-sup-0001){ref-type="supplementary-material"}). In our cohort, three patients carried deletions including *RORB* and exhibited ID and generalized epilepsy, including absence seizures with eyelid myoclonia, and autistic features in one patient, supporting a role for *RORB* in GGE and, more broadly, in several neurodevelopmental disorders.

Among the syndromic pathogenic autosomal CNVs, we identified three patients with duplications mapping to the 17p11.2 Potocki‐Lupski syndromic region, which is reciprocal to the Smith‐Magenis deletion syndrome in which epilepsy is often seen.[33](#epi14683-bib-0033){ref-type="ref"} These three patients had a phenotype consistent with Potocki‐Lupski syndrome; the occurrence of epilepsy supports previous evidence of its presence as a rare feature of 17p11.2 duplications.[5](#epi14683-bib-0005){ref-type="ref"} Interestingly, we identified five patients with a 7q11.23 deletion containing the Williams‐Beuren region; four of these individuals had Lennox‐Gastaut syndrome, and the fifth (previously reported by Ramocki et al[34](#epi14683-bib-0034){ref-type="ref"}) had a generalized drug‐resistant epilepsy.

CNVs classified as pathogenic only because of large size ([Table S4b](#epi14683-sup-0001){ref-type="supplementary-material"}) represented 27% (33/122) of all the pathogenic CNVs. These CNVs included a large number of genes, but the phenotype of affected individuals was complex and we were unable to identify an association with known genetic syndromes or with candidate epilepsy genes. However, for one individual with EE and a large de novo 13q13.1‐q13.3 deletion, we can suggest that a key gene is *NBEA*, which was reported as a possible EE gene through an in silico prioritization approach[35](#epi14683-bib-0035){ref-type="ref"} and was recently associated with neurodevelopmental disease with epilepsy.[36](#epi14683-bib-0036){ref-type="ref"}

Four of the CNVs we classified as large and pathogenic were inherited. Interestingly, a duplication on 12q21.31 was inherited from a mother with a family history of autism. Autism has been reported in Decipher in a patient carrying an overlapping duplication ([Table S4b](#epi14683-sup-0001){ref-type="supplementary-material"}). Following our algorithm, we consider these CNVs pathogenic, noting the incomplete penetrance often characterizing neurological and epileptic disorders and because we could not exclude related neurological traits in the transmitting parent.

A possibly pathogenic autosomal CNV was identified in 1.7% of the patients. As well as some known epilepsy genes, discussed in the results section, we propose other genes in these regions that can be considered potential candidates for causing epilepsy, but need further validation. We found a de novo 18q12.3 deletion, which only encompassed the gene *SETBP1*. Heterozygous missense mutations in *SETBP1* cause Schinzel‐Giedion syndrome (OMIM \#269150), characterized by severe ID and specific craniofacial features,[37](#epi14683-bib-0037){ref-type="ref"} wherein seizures also occur.[38](#epi14683-bib-0038){ref-type="ref"}, [39](#epi14683-bib-0039){ref-type="ref"} Mutations leading to haploinsufficiency, such as the deletion in our patient, have been reported in association with a distinct neurological syndrome, which includes mild to moderate ID without the typical syndromic craniofacial features.[17](#epi14683-bib-0017){ref-type="ref"}, [40](#epi14683-bib-0040){ref-type="ref"}, [41](#epi14683-bib-0041){ref-type="ref"} The patient in this study only showed severe epilepsy and ID, suggesting that the *SETBP1*‐mutation phenotype may be broader than previously described. One patient had a microdeletion, classified here as possibly pathogenic, which includes *STAG1*, now linked with epilepsy as a cohesinopathy,[24](#epi14683-bib-0024){ref-type="ref"} and one patient carried a de novo intragenic duplication in *FGF12* in which SNVs have recently been reported in patients with epileptic encephalopathies.[25](#epi14683-bib-0025){ref-type="ref"}

Other interesting candidate genes are highlighted in Table [3](#epi14683-tbl-0003){ref-type="table"} and include *HCN2*,*FMN2*,*CHRM3*,*CSNK1G3*, and *NMT1*.

Eleven patients (1%) in our study cohort had a double hit (including pathogenic and possibly pathogenic CNVs). Here, the CNV burden alone could contribute to the neurodevelopmental phenotype; as shown by Girirajan and colleagues,[42](#epi14683-bib-0042){ref-type="ref"} children with two or more rare and large CNVs of unknown significance were eight times more likely to have developmental delay compared to controls, possibly by disruption of dosage‐sensitive genes.[42](#epi14683-bib-0042){ref-type="ref"} We note, however, that our analysis focused only on CNVs with a certain pathogenic meaning and as such gives no insight into the general burden of CNVs per patient.

The enrichment analysis showed a significant association of pathogenic autosomal CNVs with nonneurological disorders and dysmorphism (for both large pathogenic and any pathogenic CNV); large pathogenic CNVs showed a more profound and significant association with dysmorphism and non‐neurological disorders only. An enrichment of CNVs in patients with dysmorphism has been observed in previous studies,[4](#epi14683-bib-0004){ref-type="ref"} underscoring the importance of testing for CNVs in patients with epilepsy and associated comorbidities. Likewise, results from our data compared to historical controls, from a systematic literature review and meta‐analysis, confirm that the percentages of pathogenic CNVs, when the phenotype includes or excludes epilepsy, do not vary significantly. Thus, although a search for CNV is undoubtedly worthwhile in people with epilepsy plus, it may not be that such CNVs drive only epilepsy, but for patients ascertained through their epilepsy, the presence of additional features points to an elevated likelihood of finding an underlying pathogenic CNV. We hypothesize that although epilepsy as a phenotype does not add a quantitative contribution to the diagnostic yield, its presence could be related to the type, location, and gene content of an underlying pathogenic CNV. Results from our data, comparing patients with epilepsy‐EE versus historical controls with epilepsy‐notEE, showed a nonsignificantly lower yield of pathogenic CNVs in patients with EE, raising a possible hypothesis that when epilepsy manifests as EE, the likelihood of finding a pathogenic CNV decreases and that EE is more often the consequence of single gene mutations.

Our study has limitations beyond its retrospective structure. The filtering workflow used allowed us to obtain a systematic classification of the large number of CNVs examined, but we recognize it is not perfect and might not accurately classify CNV mapping to hypervariable chromosomal regions. Pathogenic CNVs could be missed due to filtering out of small CNVs, misclassification of abnormalities, or an incomplete list of genes associated with epilepsy (new epilepsy‐related genes continue to be reported). We excluded the sex chromosomes from the CNV calling and subsequent analysis, because copy number calling from these chromosomes is prone to false‐positive calls and might inflate the reported frequencies of diagnostically relevant CNVs as the X chromosome in particular has been associated with neurodevelopmental disorders. Also, recessive disease cannot be ruled out with this type of analysis unless the second allele is studied with another approach.

In conclusion, we highlight the pathogenic causative role of autosomal CNVs in almost 11% of patients (and up to 12.7% when also considering the possibly pathogenic) with unexplained epilepsy with comorbidities and reiterate the concept that CNVs should be sought in patients with seizures especially when associated with other neurological and nonneurological conditions.

This study opens new perspectives for a better understanding and evaluation of CNVs identified in patients with epilepsy plus. We show that the reinterpretation of preexisting data using an adapted workflow can highlight new findings, and we recommend periodic systematic review of preacquired genetic data, as new methods and data become available. The workflow used here, specifically designed for epilepsy, can be used to homogenize data from different cohorts often collected at different times. Establishing the causative role of some CNVs can be challenging, especially when the CNV is not associated with a known syndrome, or similar CNVs may not be of the same size, might include different genes, and not have familial segregation data available to help interpretation. Bespoke, disease‐specific algorithms may assist in assignment of CNVs to diagnostic categories that are more definitive than either "possibly pathogenic" or "of unknown significance." There remain CNVs whose role will only be clarified by increasing the number of cases studied, functional studies, and continued exchange between clinicians and laboratory scientists. This study represents the first project of a newly formed and growing international consortium for CNVs in epilepsy (EpiCNV), in which large‐scale data aggregation and sharing will be utilized as a new tool for CNV and gene identification in the epilepsies.
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